Evidence map›Paper›PMID 39352409›Full record

ArticleCritical care explorations2024

Evaluation of Vancomycin Dose Needed to Achieve 24-Hour Area Under the Concentration-Time Curve to Minimum Inhibitory Concentration Ratio Greater Than or Equal to 400 Using Pharmacometric Approaches in Pediatric Intensive Care Patients.

Dawoon Jung, Omayma A Kishk, Adnan T Bhutta, Ginny E Cummings, Hana M El Sahly, Manpreet K Virk, Brady S Moffett, Jennifer L Morris Daniel, Amy Watanabe, Nicholas Fishbane and 6 more

Abstract read
In one paragraph

Article in Critical care explorations, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Vancomycin loading dose and AUCPediatric research · 2026
    Article
  3. Feasibility of vancomycin AUCFrontiers in pharmacology · 2026
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Dawoon JungCenter for Translational Medicine, University of Maryland School of Pharmacy, Baltimore, MD.ORCID 0000-0003-0947-7588
Omayma A KishkDepartment of Pharmacy, University of Maryland Medical Center, Baltimore, MD.
Adnan T BhuttaDivision of Pediatric Critical Care Medicine, Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD.
Ginny E CummingsDepartment of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD.
Hana M El SahlyDepartments of Molecular Virology and Microbiology and Medicine, Baylor College of Medicine, Houston, TX.
Manpreet K VirkDepartment of Pediatrics, Section of Critical Care Medicine, Texas Children's Hospital Baylor College of Medicine, Houston, TX.
Brady S MoffettDepartment of Pharmacy, Texas Children's Hospital, Houston, TX.
Jennifer L Morris DanielDepartment of Pharmacy, Texas Children's Hospital, Houston, TX.
Amy WatanabeThe Emmes Company, LLC, Rockville, MD.
Nicholas FishbaneThe Emmes Company, LLC, Rockville, MD.
Karen L KotloffDepartment of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD.
Kenan GuDivision of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD.
Varduhi GhazaryanDivision of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD.
Jogarao V S GobburuCenter for Translational Medicine, University of Maryland School of Pharmacy, Baltimore, MD.
Ayse Akcan-ArikanDivisions of Critical Care Medicine and Nephrology, Department of Pediatrics, Texas Children's Hospital Baylor College of Medicine, Houston, TX.
James D CampbellDepartment of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD.

Funding

VTEU SupplementUM1AI148689 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Karen L. Kotloff · 2020 to 2026
$52.7M
NIAID NIH HHS HHSN272201300015CNIAID NIH HHS HHSN272201300015INIAID NIH HHS HHSN272201300022CNIAID NIH HHS HHSN272201300022INIAID NIH HHS UM1 AI148689
6 · The paper itself

Abstract

objectivesTo investigate which independent factor(s) have an impact on the pharmacokinetics of vancomycin in critically ill children, develop an equation to predict the 24-hour area under the concentration-time curve from a trough concentration, and evaluate dosing regimens likely to achieve a 24-hour area under the concentration-time curve to minimum inhibitory concentration ratio (AUC24/MIC) greater than or equal to 400.

designProspective population pharmacokinetic study of vancomycin.

settingCritically ill patients in quaternary care PICUs. PATIENTS: Children 90 days old or older to younger than 18 years who received IV vancomycin treatment, irrespective of the indication for use, in the ICUs at the University of Maryland Children's Hospital and Texas Children's Hospital were enrolled.

interventionsVancomycin was prescribed at doses and intervals chosen by the treating clinicians. MEASUREMENTS AND MAIN

resultsA median of four serum levels of vancomycin per patient were collected along with other variables for up to 7 days following the first administration. These data were used to characterize vancomycin pharmacokinetics and evaluate the factors affecting the variability in achieving AUC24/MIC ratio greater than or equal to 400 in PICU patients who are not on extracorporeal therapy. A total of 302 children with a median age of 6.0 years were enrolled. A two-compartment model described the pharmacokinetics of vancomycin with the clearance of 2.76 L/hr for a typical patient weighing 20 kg. The glomerular filtration rate estimated using either the bedside Schwartz equation or the chronic kidney disease in children equation was the only statistically significant predictor of clearance among the variables evaluated, exhibiting equal predictive performance. The trough levels achieving AUC24/MIC = 400 were 5.6-10.0 μg/mL when MIC = 1 μg/mL. The target of AUC24/MIC greater than or equal to 400 was achieved in 60.4% and 36.5% with the typical dosing regimens of 15 mg/kg every 6 and 8 hours (q6h and q8h), respectively.

conclusionsThe pharmacokinetics of vancomycin in critically ill children were dependent on the estimated glomerular filtration rate only. Trough concentrations accurately predict AUC24. Typical pediatric vancomycin dosing regimens of 15 mg/kg q6h and q8h will often lead to AUC24/MIC under 400.

Indexed as

Anti-Bacterial AgentsArea Under CurveCritical IllnessIntensive Care Units, PediatricMicrobial Sensitivity TestsVancomycinAdolescentChildChild, PreschoolFemaleHumansInfantMaleProspective StudiesAnti-Bacterial AgentsVancomycin

Identifiers

PMID39352409
PMCPMC11446596

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.